Brief: Pharmaust Says US FDA Grants Co's Pre-Ind Meeting For Monepantel For Treatment Of MND/ALS
01/01/2024 23:02
Jan 2 (Reuters) - Pharmaust Ltd PAA.AX :
* US FDA GRANTS PHARMAUST PRE-IND MEETING FOR MONEPANTEL FOR
TREATMENT OF MND/ALS
* PROVIDES CO WITH OPPORTUNITY TO RECEIVE FEEDBACK FROM FDA
ON
PROPOSED ONGOING DEVELOPMENT PROGRAM TO RECEIVE ACCELERATED
APPROVAL
Source text for Eikon: ID:nASX4CwBSj
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility